Treatment of anti-NMDA receptor encephalitis—time to be bold?

Treatment of anti-NMDA receptor encephalitis—a recently identified cause of autoimmune encephalitis—with aggressive immunosuppressive therapies has been a subject of debate. Now, a large observational cohort study suggests that most patients respond to immunotherapy, and that second-line therapies s...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Neurology Vol. 9; no. 4; pp. 187 - 189
Main Authors Panzer, Jessica A., Lynch, David R.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.04.2013
Subjects
631/378/371
692/699/249/1313
692/700/565/251/1574
Medicine
Medicine & Public Health
Neurology
news-and-views
Online AccessGet full text

Cover

More Information
Summary:Treatment of anti-NMDA receptor encephalitis—a recently identified cause of autoimmune encephalitis—with aggressive immunosuppressive therapies has been a subject of debate. Now, a large observational cohort study suggests that most patients respond to immunotherapy, and that second-line therapies such as rituximab and cyclophosphamide may be beneficial.
ISSN:1759-4758
1759-4766
DOI:10.1038/nrneurol.2013.31